Improving care for Veterans with non-alcoholic fatty liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This intervention focuses on enhancing the diagnosis and treatment of non-alcoholic fatty liver disease (NAFLD) among Veterans by implementing a Clinical Care Pathway (NCCP). The NCCP utilizes an algorithmic approach to identify at-risk patients, assess their risk of severe NAFLD, and educate primary care providers on appropriate management strategies. The study aims to compare the effectiveness of this structured intervention against usual care in increasing diagnosis rates and facilitating referrals for treatment. By addressing the significant gap in care for NAFLD within the VA system, the study seeks to improve patient outcomes and reduce complications associated with the disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patient Aligned Care Teams (PACT) at the Michael E. DeBakey VA Medical Center

Exclusion Criteria:

* The investigators will exclude PACTs with unstable leadership (i.e., pending departure, vacancy) at time of randomization
* PACTs participating in the focus groups in Aim 1 will be excluded in Aim 2 to avoid cross contamination
* PACTs meeting the following criteria will be excluded from randomization in Aim 2:

  * PACTs who do not treat NAFLD
  * PACTs not located at the main hospital
  * PACTs with less than 100 visits within 3 months

Where it's running

• Michael E. DeBakey VA Medical Center, Houston, TX
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Hashem B. El-Serag, MD MPH — Michael E. DeBakey VA Medical Center, Houston, TX
• Study coordinator: Hashem B El-Serag, MD MPH
• Email: Hashem.El-Serag@va.gov
• Phone: (713) 794-8640

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low‑methoxy pectin for inflammation, gut microbiome, and metabolic health in MASLD

  This tests whether taking daily low‑methoxy pectin for six weeks can reduce inflammation and improve gut bacteria and metabolic markers in adults with MASLD.

  Recruiting at 3 sites University of Nottingham · Nottingham, United Kingdom and 2 other locations · NCT07093346

• Ultraportable Hepatoscope ultrasound for measuring liver fat in MASLD/MASH

  The Hepatoscope device will be tested to see if it can measure liver fat accurately in adults with MASLD/MASH compared with MRI-PDFF.

  Recruiting at 2 sites E-Scopics · Angers and 2 other locations · NCT06661655

• Digoxin for NASH with stage 2–3 fibrosis

  This trial will see if taking once-daily digoxin helps clear NASH and reduce liver scarring in adults with biopsy-confirmed NASH and stage 2–3 fibrosis.

  Recruiting at 2 sites Phase 2 Yale University · New Haven, Connecticut and 1 other locations · NCT06588699

• Reset-INSPIRE: See if CGM can reveal insulin sensitivity in people at risk for MASLD

  This study tests whether real-time CGM data can accurately reflect insulin sensitivity in adults without diabetes who are at risk for MASLD.

  Recruiting National University Health System, Singapore · Singapore, Singapore · NCT07861191

• ALN-CIDEB in adults with MASLD to see if it helps the liver

  This study tests whether ALN-CIDEB can help adults with MASLD and its liver damage compared to placebo.

  Recruiting at 4 sites Phase 3 Regeneron Pharmaceuticals · Miami, Florida and 3 other locations · NCT07854782

• Peanut intake and liver health in adults with MASLD

  This study tests whether adding peanuts to daily meals for 12 weeks can improve liver markers and metabolic health in adults with MASLD.

  Recruiting Henry Ford Health System · Detroit, Michigan · NCT07646197

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.